Retinalamin
Ретиналамин
Target Organ
Retina
Description
Retinalamin is a peptide-based medication derived from animal retinal tissue (calves). It represents a breakthrough in treating degenerative eye diseases, particularly those affecting the retina. Retinalamin stimulates photoreceptor regeneration, improves metabolism in the retinal pigment epithelium (RPE), enhances microcirculation in retinal blood vessels, and has been shown to restore visual acuity, expand visual fields, and slow the progression of retinal degeneration. It is used extensively in Russia for glaucoma, macular degeneration, diabetic retinopathy, and post-traumatic retinal dystrophies. The medication must be administered via injection—either parabulbar (near the eye) or intramuscularly.
⚙️ Mechanism of Action
Stimulates regeneration of photoreceptor cells (rods and cones), improves metabolic activity in retinal pigment epithelium, enhances microcirculation in retinal vessels, and provides trophic support to all retinal cell layers.
✓ Primary Benefits
- ·Restores and improves visual acuity
- ·Expands visual fields in glaucoma and retinal dystrophies
- ·Slows progression of age-related macular degeneration
- ·Supports recovery from retinal injuries and inflammation
💊Dosing Protocol
Standard Course
5-10mg once daily parabulbar or intramuscularly for 5-10 days; repeat every 3-6 months as needed
🏥Clinical Applications
Synergistic Stacks
Scientific Validation
Retinalamin in Diabetic Retinopathy: A Randomized Controlled Trial
Landmark RCT showing Retinalamin reduces diabetic macular edema and improves visual acuity in patients with diabetic retinopathy.
Retinalamin in the Treatment of Primary Open-Angle Glaucoma
Clinical study evaluating the neuroprotective effects of Retinalamin in patients with primary open-angle glaucoma.